Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.58 |
| ▸ | TUBB | P07437 | 3/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.58 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.58 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.58 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.58 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.58 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.58 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.58 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | XBP1 | P17861 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29819713 | 1.00 | TUBB4A (0.58) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8938320 | 0.89 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4405258 | 0.89 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4409843 | 0.86 | TUBB4A (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4406192 | 0.86 | TUBB4A (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4395705 | 0.85 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4329236 | 0.84 | TUBB4A (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14374451 | 0.83 | TUBB4A (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14194793 | 0.83 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4401484 | 0.83 | KDM4E (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260081-B | Sulfonamide indole aryl sulfone derivative and preparation method and application thereof | 山东大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-112920208-B | Boric acid-containing indole aryl sulfone derivative and preparation method and application thereof | 山东大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-115260081-A | Sulfonamide indole aryl sulfone derivative and preparation method and application thereof | 山东大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-112898193-B | Indole aryl sulfone derivative and preparation method and application thereof | 山东大学 | 2022-08-05 | — | — | CN | disclosed |
| CN-112920208-A | Boric acid-containing indole aryl sulfone derivative and preparation method and application thereof | 山东大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-112898193-A | Indole aryl sulfone derivative and preparation method and application thereof | 山东大学 | 2021-06-04 | — | — | CN | disclosed |
| EP-1390029-B1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2009-12-16 | — | — | EP | disclosed |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | disclosed |
| EP-1915055-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | LACOLLA PAULO | 2007-12-20 | — | — | US | disclosed |
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | LACOLLA PAULO | 2007-12-20 | — | — | US | disclosed |
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | LACOLLA PAULO | 2007-12-20 | — | — | US | disclosed |
| WO-2007021629-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1390029-A4 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2005-11-30 | — | — | EP | disclosed |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| US-6710068-B2 | PHENYLSULFONYLINODLES USEFUL FOR THE TREATMENT OF HIV IN HUMANS AND OTHER HOST ANIMALS | IDENIX PHARMACEUTICALS, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1390029-A1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | Idenix (Cayman) Limited (KY) | 2004-02-25 | — | — | EP | disclosed |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002083126-A1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX (CAYMAN) LIMITED (KY) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | TUBB4A 321/4885TUBB 326/4885TUBA3C 516/4885 |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | TUBB4A 321/4885TUBB 326/4885TUBA3C 516/4885 |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | TUBB4A 321/4885TUBB 326/4885TUBA3C 516/4885 |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | TUBB4A 2792/4885TUBB 2020/4885TUBA3C 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.